This post was originally published on this site
The company now sees 2023 sales growth of 32-38%, versus its prior outlook of 27-33%. They see operating profit growth of 40-46%, versus its prior outlook of 31-37%.
Novo said the updated sale outlook is “… primarily reflecting higher full-year expectations for Ozempic® volumes sold in the US and gross-to-net sales adjustments for Ozempic® and Wegovy® in the US.”
For the third quarter, sales increased by 33% and operating profit increased by 37%.
The news is also boosting Eli Lilly and Company (NYSE:LLY) shares, which has its own weight loss drug. Eli Lilly stock is up 1% in pre-open trading.
